La Jolla-based Dermtech, a developer of non-invasive, gene expression tests for helping to diagnose skin cancer, has filed for an IPO. According to the company, it is looking to raised $25.0M in its IPO, and has applied to list on the NASDAQ Capital Market as DMTK. The company's IPO is being underwritten by Maxim Group LLC and Feltl and Company. The company is backed by angel investors, including Gary Jacobs and his firm, Jacobs Investment Company, as well as angels from the Tech Coast Angels.
Top NewsTuesday, May 13, 2014
Dermtech Files For IPO